Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women�s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors, and a direct sales force. Internationally, it sells and markets primarily in Japan and Europe through distributor arrangements. It provides diagnostic testing solutions under various brand names, including QuickVue, QuickVue+, Quidel, MicroVueTM, FreshCells , D3 FastPoint, Super E-Mix, ELVIS, Sofia , Quidel Molecular, and Thyretain. In May 2013, the Company completed the acquisition of BioHelix Corporation.